Spots Global Cancer Trial Database for follicular lymphoma (fl)
Every month we try and update this database with for follicular lymphoma (fl) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | NCT03768505 | Follicular Lymp... Non Hodgkin Lym... Marginal Zone L... | Zandelisib (ME-... | 18 Years - | MEI Pharma, Inc. | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | NCT02290951 | Non-Hodgkin Lym... Chronic Lymphoc... | Odronextamab mu... Odronextamab mu... | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | NCT03547115 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Chronic Lymphoc... Diffuse Large B... Acute Myeloid L... | voruciclib mono... voruciclib and ... | 18 Years - | MEI Pharma, Inc. | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | NCT05720052 | Relapsed or Ref... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... Marginal Zone L... | MS-553 | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms | NCT06043011 | Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenström's M... | Routine care as... | 18 Years - | iOMEDICO AG | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | NCT06191744 | Follicular Lymp... | Epcoritamab Prednisone Rituximab Lenalidomide Doxorubicin Vincristine Cyclophosphamid... Obinutuzumab Bendamustine | 18 Years - | AbbVie | |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | NCT02290951 | Non-Hodgkin Lym... Chronic Lymphoc... | Odronextamab mu... Odronextamab mu... | 18 Years - | Regeneron Pharmaceuticals | |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | NCT04982471 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | 18 Years - | Celgene | ||
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | NCT03424122 | B-cell Lymphoma | Parsaclisib Rituximab Bendamustine Ibrutinib | 18 Years - | Incyte Corporation | |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 | NCT03265158 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | NCT03571828 | Diffuse Large B... Mantle Cell Lym... Follicular Lymp... | AMG 562 | 18 Years - 100 Years | Amgen | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) | NCT04049513 | Lymphomas Non-H... Diffuse Large B... Primary Mediast... Transformed Fol... Follicular Lymp... Mantle Cell Lym... | WZTL002-1 (1928... Cyclophosphamid... | 16 Years - 75 Years | Malaghan Institute of Medical Research | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | NCT06191744 | Follicular Lymp... | Epcoritamab Prednisone Rituximab Lenalidomide Doxorubicin Vincristine Cyclophosphamid... Obinutuzumab Bendamustine | 18 Years - | AbbVie | |
| ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) | NCT04049513 | Lymphomas Non-H... Diffuse Large B... Primary Mediast... Transformed Fol... Follicular Lymp... Mantle Cell Lym... | WZTL002-1 (1928... Cyclophosphamid... | 16 Years - 75 Years | Malaghan Institute of Medical Research | |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 | NCT03265158 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | NCT04745832 | Follicular Lymp... Non Hodgkin Lym... Marginal Zone L... | Zandelisib Rituximab Bendamustine CHOP | 18 Years - | MEI Pharma, Inc. | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab | |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | NCT04830137 | Chronic Lymphoc... Small Lymphocyt... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... Follicular Lymp... Diffuse Large B... Primary Central... | NX-2127 | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study to Assess the Long-term Safety of Tazemetostat | NCT02875548 | Diffuse Large B... Follicular Lymp... Synovial Sarcom... Epitheliod Sarc... Mesothelioma Advanced Solid ... Renal Medullary... Non-Hodgkin Lym... | Tazemetostat | 18 Years - | Ipsen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
